Sophia Z, Humphreys, PharmD, MHA

home / authors / sophia-z-humphreys-pharmd-mha

Articles

Pills spilling out of pill bottle | Image credit: New Africa - stock.adobe.com

Patient-Centered Approach Helps Ensure Biosimilar Adoption Success

Sophia Z, Humphreys, PharmD, MHA
March 21st 2023

Educating patients, providers improves acceptance, trust as number of approvals, indications grows

Read More

Biosimilar Market Outlook Looks Strong

Biosimilar Market Outlook Looks Strong

Sophia Z, Humphreys, PharmD, MHA
January 24th 2023

Pipeline includes more than 100 products encompassing bone health, cancer care, immunosuppressants, ophthalmology.

Read More

Front-Line Clinicians Investigate COVID-19 Treatments

Front-Line Clinicians Investigate COVID-19 Treatments

Sophia Z, Humphreys, PharmD, MHA
March 25th 2020

Here is an overview of reported investigations of existing medications.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD